HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q3 2023 13F Holders as of 30 Sep 2023

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
121,448,513
Share change
-59,507
Total reported value
$4,640,515,924
Put/Call ratio
45%
Price per share
$38.20
Number of holders
384
Value change
+$384,195
Number of buys
175
Number of sells
170

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q3 2023

As of 30 Sep 2023, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 384 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 121,448,513 shares. The largest 10 holders included BlackRock Inc., VANGUARD GROUP INC, Artisan Partners Limited Partnership, STATE STREET CORP, SNYDER CAPITAL MANAGEMENT L P, MACQUARIE GROUP LTD, ALLIANCEBERNSTEIN L.P., JPMORGAN CHASE & CO, GEODE CAPITAL MANAGEMENT, LLC, and MARSHALL WACE, LLP. This page lists 389 institutional shareholders reporting positions in this security for the Q3 2023 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.